Prescient Therapeutics Investor Briefing – 4 August
Prescient Therapeutics (ASX: PTX) Webcast Replay
Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Steven Yatomi-Clarke, provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 4 August 2021 at 12pm (AEST).